Rx/reimbursement adult incontinence witnessed continued growth in 2024, mainly because more elderly people and patients with chronic conditions are using these products. Better reimbursement policies and easier access to medical supplies mean more Estonians can access the products they need. Hospitals and healthcare providers are also recommending high-quality, medical-grade options, increasing demand. As awareness grows and support improves, more people are taking advantage of reimbursement sch

The rate of growth in retail current value sales of Rx/reimbursement adult incontinence slowed slightly in 2024. As the elderly population grows, there is a corresponding surge in the demand for prescriptions and reimbursements for adult incontinence products, reflecting the importance of these products to many ageing individuals. This trend underscores the pressing need for policymakers and healthcare providers to anticipate and address the evolving needs of the elderly population, ensuring the

After the dynamic performance seen in recent years, Rx/reimbursement adult incontinence saw volume and value growth slow considerably in 2024. The steep rise in sales over 2023 stemmed from legislative changes, effectively increasing the monthly allowance of adult incontinence products provided under prescription. With consumers able to access more products under prescription, retail sales plummeted in 2023, with the government effectively subsidising more sales via Rx.

Value sales of Rx/reimbursement adult incontinence in Austria witnessed a steady rise in 2024, although growth subsided in line with falling inflation. The rising number of older consumers requiring consistent care has increased demand for reimbursed adult incontinence products. An ageing population positively impacts demand for Rx/reimbursement adult incontinence, as the likelihood of suffering from incontinence increases with age. Many Austrian consumers are consulting doctors more frequently

In 2024, Rx/reimbursement adult incontinence maintained similar low volume and current value growth to previous years, despite persistent challenges. The category faced notable obstacles, particularly within health units, where product shortages, especially in the traditional tab-style format, created difficulties for older individuals. Long waiting times and delays in scheduling examinations further compounded issues for those reliant on these essential products. The post-pandemic environment a

Rx/reimbursement adult incontinence in the UK continued to record volume declines in 2024, due to strong competition from retail adult incontinence. Although the category experienced value growth in 2022 and 2023, this was a result of a strong increase in unit prices, as inflation and the cost of production skyrocketed. However, as inflation in the UK marginally eased in 2024, the category returned to a weak value sales performance more in line with volume sales.

Value sales of Rx/reimbursement adult incontinence products rose in 2024. The increase was driven by a growing elderly population requiring long-term care and more consistent support in managing incontinence. In the context of economic uncertainty, many consumers turned to the healthcare system to obtain prescriptions for reimbursable products, reducing their personal financial burden. This has contributed to a rise in consultations and an increased uptake of reimbursed products, particularly am

Value sales of RX/reimbursement adult incontinence in Croatia experienced robust growth in 2024. The buoyant performance can be directly linked to the country's ageing population and the established reimbursement system through HZZO. As the number of elderly individuals rises, so too does demand for prescribed and reimbursed incontinence products. Furthermore, increased awareness among healthcare professionals and the public regarding available reimbursement options has likely contributed to thi

In 2024, Rx/Reimbursement adult incontinence in Slovenia posted moderate volume growth and a healthy, if slower than in 2023, increase in current value sales, supported by residual inflationary pressure on prices. As in retail, Rx/Reimbursement adult incontinence’s performance benefited from the ageing population trend, as well as improvements in public health investments. This development was driven primarily by the rising demand from healthcare institutions. Amid the ageing population trend, a

While demand for rx/reimbursement adult incontinence in Australia continued to steadily rise in 2024, value growth was much higher. By increasing awareness and education among healthcare professionals, particularly in general practice settings, more individuals experiencing incontinence are being identified and referred, which is resulting in an increase in the utilisation of prescription or reimbursed adult incontinence products as part of a management approach.

Sales of Rx/reimbursement adult incontinence saw strong value growth in Turkey in 2024, with volume growth notably lower. This aligns with the cross-category trend of value being more strongly supported by high prices. Whilst retail adult incontinence saw stronger value growth in 2024, compared to Rx/reimbursement options, Rx/reimbursement adult incontinence is a larger category in both value and volume terms. Indeed, a significant portion of overall adult incontinence product sales is accounted

Rx/reimbursement adult incontinence in Kazakhstan continued to develop positively in 2024, with volume and current value growth rates improving from 2023. As was the case at the retail level, expansion was primarily driven by the fact that the incidence of incontinence problems in the country is increasing in tandem with population ageing. At the same time, rising health-consciousness and the gradual erosion of the taboo surrounding incontinence means consumers are becoming more willing to seek

Rx/reimbursement adult incontinence registered healthy current value and volume growth in Serbia in 2024, with an ageing population supporting growth. In addition, with consumer purchasing power under pressure, more users have sought medical prescriptions to help with the cost of adult incontinence.

Value sales of prescription (RX) and reimbursement adult incontinence products increased in 2024, driven by several key factors. Firstly, Belgium's aging population continued to create consistent demand for these products. Additionally, the rising need for reimbursement for adult incontinence was exacerbated by high inflation and financial instability affecting some Belgians. As a result, both value and volume sales of RX and reimbursement adult incontinence products saw significant growth in 20

In 2024, reimbursement adult incontinence saw significant sales growth in Spain. The Spanish healthcare system has adopted a clear strategy by prioritising reimbursement for products specifically designed to manage severe incontinence. This framework reflects not only a commitment to improving patient care but also a recognition of the significant growth potential. The system provides financial support for a range of essential supplies such as super absorbent briefs, all-in-one diapers, pull-up

The landscape of Rx/reimbursement adult incontinence in Slovakia underwent notable changes in 2024 due to regulatory adjustments. From April 2024, new legislation was introduced to refine the prescription process, mandating that doctors indicate the specific level of incontinence on a designated voucher. This measure was intended to streamline the reimbursement process and ensure that patients receive products tailored to their medical needs. Additionally, the financial limit for patients classi

In 2024, Rx/reimbursement adult incontinence in Poland continued to post healthy retail volume and current value growth, albeit slower than in 2023 and other years of the review period. As in the retail sphere, demand increased alongside a growing number of consumers in older cohorts, who are more likely to suffer with incontinence problems. Programmes for reimbursement gained traction, as this demographic trend increased the prevalence of urinary incontinence. As the population ages, the need f

RX/reimbursement adult incontinence saw steady growth in value and volume terms in 2024. Value growth was primarily driven by two key factors: Sweden’s ageing population and the rising prevalence of obesity and type 2 diabetes. A strong correlation exists between age, underlying health conditions and incontinence. The population aged 65+ continues to grow annually, while obesity and type 2 diabetes remains a significant public health concern. According to the Swedish Health Authority, approximat

Current value sales growth of Rx/reimbursement adult incontinence products in Hungary in 2024 was significantly higher compared to retail adult incontinence products. as local consumers could be reimbursed by up to 80% by insurance companies. Doctors determine the appropriate payment group for each consumer based on their specific incontinence issues and identify the most suitable product for them to use. As a result, Rx/reimbursement became the primary choice for many local consumers looking fo

Value sales of RX/reimbursement adult incontinence increased in 2024, driven by an ageing population and a rising obesity rate. The natural expansion of the potential user base contributed to steady demand, while growing health consciousness and hygiene awareness further encouraged individuals to seek medical assistance for incontinence issues. The long-term impact of the COVID-19 pandemic has also played a role in shaping attitudes toward personal wellbeing, reducing stigma around seeking medic

Value sales of RX/reimbursement adult incontinence grew in 2024 in Denmark, supported by the ageing population. It is estimated that around 80% of reimbursement recipients are aged 65 and older, a group that is expanding as life expectancy increases. The ageing population, coupled with rising obesity rates, underpins the recorded growth for RX/reimbursement adult incontinence in 2024, due to the strong link between older age, obesity, and incontinence.

Rx/reimbursement adult incontinence saw volume and value growth in the Czech Republic in 2024. The growth of the category is being fuelled not just by the ageing population but also by more information about Rx rights and reimbursements via magazines and pharmacies. Since 1 January 2024, the VAT rate has been reduced from 15% to 12% and this change has been reflected in the price of incontinence products. Patient co-payment remained unchanged. The new law also introduced an adjustment of the rei

In 2024, value sales for RX/reimbursement adult incontinence products grew, although the distribution of adult diapers is largely unaffected by economic cycles. The users of adult diapers distributed by the government are primarily elderly or disabled individuals with limited mobility, making these products essential.

Value sales of RX/reimbursement adult incontinence increased modestly in 2024, but negative volume growth continued to exert downward pressure on overall performance. Many consumers opted to purchase incontinence products through retail channels or e-commerce platforms rather than rely on reimbursed options. The primary reasons for this shift included the flexibility, discretion, and broader product variety available outside of the reimbursement system.